eNRGy:朝着NRG1融合阳性癌症的未来迈进
Lucia Anna Muscarella1, Massimo Di Maio2
1Laboratory of Oncology, Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.
Med (New York, N.Y.)
|April 12, 2025
概括
泽诺库图祖马布对具有NRG1融合的晚期癌症,包括肺和胰腺类型,显示出有前途. 综合基因融合测试对于识别可能受益于这种向治疗的患者至关重要.
科学领域:
- 在瘤学瘤学.
- 分子诊断学 分子诊断学
- 遗传学 是一个遗传学.
背景情况:
- NRG1基因融合是一种罕见的驱动突变,在各种固体瘤中发现.
- 针对具有特定分子变化的癌症,有针对性的疗法正在出现.
研究的目的:
- 评估在患有具有NRG1基因融合的先进固体瘤的患者中使用泽诺库图祖马布的疗效和安全性.
- 探索泽诺库图祖马布作为泛瘤疗法的潜力.
主要方法:
- eNRGy试验是一项I/II期研究.
- 纳入了患有晚期固体瘤和已确认NRG1融合的患者.
- 瘤类型包括非小细胞肺癌和胰腺癌.
- 基于RNA的下一代测序被用于分子分析.
主要成果:
- 泽诺库图祖马布在具有NRG1融合的多种瘤类型中表现出显著的临床活性.
- 观察到的反应表明,除了特定的癌症组织学之外,泽诺库图祖马布的广泛疗效.
- 治疗一般耐受良好,但副作用较轻.
结论:
- NRG1基因融合在一系列固体瘤中代表了可向的脆弱性.
- 泽诺库图祖马布显示出作为NRG1融合阳性癌症的不可知疗法的潜力.
- 广泛实施全面的基因组分析,包括基因融合检测,对于患者鉴定至关重要.
更多相关视频
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
9.5K
08:02Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
5.4K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Methods of Nuclear Reprogramming
1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K
The Nucleolus
8.6K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.6K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
